The NACE Clinical Highlights Show

NACE
  • 4.7 (23)
  • Medicine
  • Updated Biweekly

Engage with expert NACE faculty for discussions about current clinical strategies for common and rare health conditions that you can use in clinical practice immediately, and that work for you and your patients.

  1. 1d ago

    CME/CE Podcast: Continuing the Conversation - Clinical Trial Updates in Asthma

    Program Description This podcast activity provides an in-depth review of several recent trials in severe asthma management, highlighting the ongoing shift in asthma precision medicine towards identifying the right patients for the right treatments. Clinicians will examine clinical data from the NIMBLE trial (depemokimab), alongside the WAYFINDER trial (tezepelumab), as well ZEPHYR 5 (benralizumab), REMOMEPO (mepolizumab), VESTIGE (dupilumab) and VALLIANT (verekitug). This activity will grant clinicians critical insights to move beyond simple exacerbation reduction and precisely align advanced biologic therapies with the underlying cellular biology driving each patient's symptoms. Educational Objective At the conclusion of this activity, participants should be better able to: Review recent updates in the asthma literature, including recent guideline revisions and evolving clinical trial data for newer biologic therapies. Accredited Providers The National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP). The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). Faculty Cedric Rutland, BS, MD, FCCP Volunteer Faculty University of California Pulmonary Critical Care Internal Medicine, Producer Rutland Medical Group Newport Critical Care Physicians Lake Forest, CA Dr. Rutland has disclosed the following financial relationships: Consultant: Sanofi (asthma, diabetes, NP, RSV, AD), Boehringer Ingelheim (IPF, PPF), Regeneron (asthma, diabetes, NP, RSV, AD), Chiesi (asthma), Baxter (bronchiectasis), Insmed (bronchiectasis), AstraZeneca (asthma, cough) Advisor/Advisory Board: Sanofi (asthma, AD, NP), Regeneron (asthma, AD), Chiesi (asthma), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough) Speaker: Sanofi (asthma, NP, AD, AFRS, urticaria, EoE), Regeneron (asthma, NP, AD, AFRS, urticaria, EoE), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough), Chiesi (asthma), Baxter (bronchiectasis) These relationships have ended within last 24 months: Consultant: GSK (asthma, cough, RSV) Advisor/Advisory Board: GSK (asthma, cough, RSV) Speaker: GSK (asthma, cough, RSV) Diego J. Maselli, MD, FCCP, ATSF Professor and Chief Division of Pulmonary Diseases & Critical Care UT Health at San Antonio Director, Respiratory Care, University Health System Director, Severe Asthma Program, University Health System San Antonio, TX Dr. Maselli has disclosed the following financial relationships: Consultant: AstraZeneca (asthma, COPD), Sanofi/Regeneron (asthma, COPD), GSK ( asthma, COPD), Amgen (asthma, COPD), Insmed (bronchiectasis) Speaker: GSK (asthma, COPD), AstraZeneca (asthma, COPD), Amgen (asthma, COPD), Sanofi/Regeneron (asthma, COPD) All of the relevant financial relationships listed for these individuals have been mitigated. Nurse Planner and Peer Reviewer Marjorie Crabtree, DNP, FNP, ANP Haymarket Medical Education Steering Committee Nurse Practitioner Healthcare Foundation Accredited Provider Program Director Bellevue, WA Dr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company. Accredited Provider Disclosure NACE staff has no relevant financial relationships to disclose. Intended Audience Pulmonology, allergy/immunology, and critical care clinicians (physicians, nurse practitioners, and physician associates), as well as primary care and geriatric medicine clinicians caring for patients with asthma. Commercial Supporters This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    18 min

  2. 1d ago

    CME/CE Podcast: Emerging Agents in PAH - Targeting Novel Pathways

    Program Description This enduring educational activity provides a comprehensive update on late stage agents being researched for the management of pulmonary arterial hypertension (PAH). Led by expert faculty, the program shifts the clinical focus from traditional vasodilators to novel investigational therapies that directly target the underlying cellular pathways responsible for pulmonary vascular remodeling and disease progression. Clinicians will gain critical insights into the mechanisms of action, latest clinical trial data, and real-world practice implications of these emerging therapeutic classes to better address unmet needs in contemporary care. At the conclusion of this activity, participants should be better able to: Discuss clinical trial data and potential clinical utility of emerging agents in PAH. Accredited Providers The National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP). Accreditation Statement The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). Intended Audience Pulmonology clinicians (physicians, nurse practitioners, and physician associates), cardiology clinicians, and primary care clinicians caring for patients with or at risk for PAH. Faculty Ioana Preston, MD Director Pulmonary Hypertension Center Lahey Hospital and Medical Center UMASS Chan Medical School Burlington, MA Dr. Preston has disclosed the following financial relationships: Consultant: Gossamer Bio, Insmed, Janssen Pharmaceuticals, Keros Therapeutics, Liquidia Technologies, Merck & Co./Acceleron Pharma, Respira Technologies, United Therapeutics Corporation Contracted Research: Gossamer, Janssen Pharmaceuticals, Merck & Co./Acceleron Pharma, Novartis, United Therapeutics Corporation Data and Safety Monitoring Board (DSMB): Tectonic Therapeutic All of her disclosures are related to PH. Jean Elwing, MD Professor of Medicine, University of Cincinnati College of Medicine Director, Pulmonary Hypertension Program, University of Cincinnati  Pulmonary, Critical Care and Sleep Medicine Cincinnati, OH Dr. Elwing has disclosed the following financial relationships: Consultant: Gossamer Bio (pulmonary hypertension), Insmed (pulmonary hypertension), Liquidia (pulmonary hypertension), United Therapeutics (pulmonary hypertension) Speaker: Merck (pulmonary hypertension) Contracted Research: Acceleron/Merck (pulmonary hypertension), Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Insmed (pulmonary hypertension), Lung LLC (pulmonary hypertension), Novartis (pulmonary hypertension), NS Pharma (pulmonary hypertension), Pharmosa/Liquidia (pulmonary hypertension), Pulmovant (pulmonary hypertension), Regeneron (pulmonary hypertension), United Therapeutics (pulmonary hypertension) These relationships ended within the last 24 months: Consultant: Inhibikase (pulmonary hypertension), Janssen/Actelion/Johnson & Johnson (pulmonary hypertension), Merck (pulmonary hypertension) Advisor/Advisory Board: Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Merck (pulmonary hypertension), United Therapeutics (pulmonary hypertension) Speaker: United Therapeutics (pulmonary hypertension) All of the relevant financial relationships listed for these individuals have been mitigated. Nurse Planner and Peer Reviewer Marjorie Crabtree, DNP, FNP, ANP Haymarket Medical Education Steering Committee Nurse Practitioner Healthcare Foundation Accredited Provider Program Director Bellevue, WA Dr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company. Accredited Provider Disclosure NACE staff have no relevant financial relationships to disclose. Commercial Supporters This activity is supported by an independent educational grant from Insmed and an independent educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    21 min

  3. 2d ago

    APAPP Cannabis and Sleep

    Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    36 min

  4. Jun 10

    CME/CE Podcast - Integrating TROP2-Directed ADCs into TNBC Treatment Plans: Novel Aspects of Efficacy and Safety Profiles

    For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800 Summary This CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice. Learning Objectives Evaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology).  For additional information about the accreditation of this program, please contact NACE at info@naceonline.com. Faculty and Moderator  Aditya Bardia, MD Program Director, Breast Medical Oncology, UCLA Professor of Medicine, UCLA Los Angeles, CA Dr. Bardia has disclosed the following financial relationships: Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome Advisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome Contracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer Stock options: Vyome (immuno-inflammatory and rare diseases) All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer. Maura Di Nicola, MD Assistant Professor of Ophthalmology Bascom Palmer Eye Institute Medical Director of Imaging and Echography Bascom Palmer Eye Institute Miami, FL Dr. Di Nicola has disclosed the following financial relationships: Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology) Advisor/Advisory Board: AbbVie (ophthalmology) Research Grant: Castle Biosciences (ocular oncology) Please review additional planner disclosures here. Disclosure of Commercial Support This educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    27 min

  5. Jun 1

    NACE Journal Club #31

    The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Orforglipron for maintenance of body weight reduction  - Nature Medicine 2026. Discussion by: Guest: Joe Gonella, MD  Resident - Abington Family Medicine Residency Program  Jefferson Health 2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026.  Discussion by:  Guest: Neil Skolnik, MD Professor of Family and Community Medicine Sidney  Kimmel  Medical College Thomas Jefferson University Associate Director - Family Medicine Residency Program Jefferson Health – Abington 3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by: Guest: Neil Skolnik, MD Professor of Family and Community Medicine Sidney  Kimmel  Medical College Thomas Jefferson University Associate Director - Family Medicine Residency Program Jefferson Health – Abington 4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.   NEJM 2026 Discussion by: Guest: Alex Sauer, MD  Resident - Abington Family Medicine Residency Program Jefferson Health Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.  This Podcast Episode does not offer CME/CE Credit.  Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    31 min

  6. May 1

    NACE Journal Club #30

    The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 2026. Discussion by: Guest: Jessica Stieritz, MD Resident - Abington Family Medicine Residency Program  Jefferson Health 2. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomized controlled trial. Lancet Rheumatology 2026. Discussion by: Guest: Neil Skolnik, MD Professor of Family and Community Medicine Sidney  Kimmel  Medical College Thomas Jefferson University Associate Director - Family Medicine Residency Program Jefferson Health – Abington 3. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. NEJM 2026 Discussion by:  Guest: Steven Leonard, MD  Resident - Abington Family Medicine Residency Program  Jefferson Health Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.  This Podcast Episode does not offer CME/CE Credit.  Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    26 min
  7. APAPP 2026 GOLD Guidelines

    Apr 1

    APAPP 2026 GOLD Guidelines

    Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    36 min
  8. APAPP Refractory Chronic Cough

    Apr 1

    APAPP Refractory Chronic Cough

    Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

    39 min
See All (140)

Ratings & Reviews

4.7
out of 5
23 Ratings

About

Engage with expert NACE faculty for discussions about current clinical strategies for common and rare health conditions that you can use in clinical practice immediately, and that work for you and your patients.

Information

  • Creator
    NACE
  • Years Active
    2019 - 2026
  • Episodes
    140
  • Rating
    Clean
  • Copyright
    © 2026 National Association for Continuing Education
  • Show Website
    The NACE Clinical Highlights Show

You Might Also Like